Pulmonary Edema Associated with Rosiglitazone and Troglitazone

No abstract is available for this paper.

• Publication year

  2001

• Venue

  The Annals of Pharmacotherapy

• Publication date

  2001-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1345/aph.10132PMID 11197573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Herbal medicines: where is the evidence?

  2000cited by this paper
• Indinavir concentrations and St John's wort.

  2000cited by this paper
• Ask patients which herbal drugs they smoke as well as eat.

  2000cited by this paper
• Herbal interactions with cardiac drugs.

  2000cited by this paper
• Acute heart transplant rejection due to Saint John's wort.

  2000cited by this paper
• Use of alternative medicine by patients undergoing cardiac surgery.

  2000cited by this paper
• St John's wort interaction with digoxin.

  2000cited by this paper
• Pulmonary edema associated with troglitazone therapy.

  1999cited by this paper
• Significant weight gain with rezulin therapy.

  1999cited by this paper
• The International textbook of cardiology

  1988cited by this paper
• A method for estimating the probability of adverse drug reactions

  1981cited by this paper

• Size-dependent macrophage-targeting of mannose-modified rosiglitazone liposomes to alleviate inflammatory bowel disease

  2023cites this paper
• Antipsychotic Drugs and Peripheral Edema: A Review

  2020cites this paper
• Antipsikotik İlaçlar ve Periferik Ödem: Bir Derleme

  2020cites this paper
• Aquaporin-4 deletion ameliorates hypoglycemia-induced BBB permeability by inhibiting inflammatory responses

  2018cites this paper
• Control of lower extremity edema in patients with diabetes: Double blind randomized controlled trial assessing the efficacy of mild compression diabetic socks.

  2017cites this paper
• Hypertension and Diabetes: Need for Combination Therapy

  2016cites this paper
• Acute Coronary Syndrome, Myocardial Infarction, Heart Failure, and Stable Coronary Artery Disease—Specific Considerations in Diabetes

  2016cites this paper
• Human in vivo studies on the non-glycaemic effects of thiazolidinedione derivatives

  2014cites this paper
• PPARγ-Induced Stimulation of Amiloride-Sensitive Sodium Current in Renal Collecting Duct Principal Cells is Serum and Insulin Dependent

  2014cites this paper
• Rosiglitazone

  2012cites this paper
• Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.

  2012cites this paper
• The Role of the Angiotensin System in Cardiac Glucose Homeostasis

  2012cites this paper
• Preserved Response to Diuretics in Rosiglitazone‐Treated Subjects With Insulin Resistance: A Randomized Double‐Blind Placebo‐Controlled Crossover Study

  2011cites this paper
• An arylidene-thiazolidinedione derivative, GPU-4, without PPARγ activation, reduces retinal neovascularization.

  2011cites this paper
• THE ROLE OF PPARγ IN KIDNEY COLLECTING-DUCT by

  2011cites this paper
• Stimulation of ENaC Activity by Rosiglitazone is PPARγ-Dependent and Correlates with SGK1 Expression Increase

  2010cites this paper
• Bioimpedance Spectroscopy for the Estimation of Body Fluid Volumes in Mice

  2010cites this paper
• Effets indésirables des thiazolidinediones chez les patients diabétiques de type 2

  2008cites this paper
• Thiazolinediones and heart failure: the potential to precipitate irreversible cardiac dysfunction.

  2008cites this paper
• Rosiglitazone-induced anasarca without heart failure: capillary leakage?

  2008cites this paper
• Renal and Vascular Mechanisms of Thiazolidinedione-Induced Fluid Retention

  2008cites this paper
• The role of Sgk-1 in the upregulation of transport proteins by PPAR-{gamma} agonists in human proximal tubule cells.

  2008cites this paper
• Chronic Rosiglitazone Therapy Normalizes Expression of ACE1, SCD1 and other Genes in the Kidney of Obese Zucker Rats as Determined by Microarray Analysis

  2008cites this paper
• Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats.

  2008cites this paper
• Cardiovascular risk of rosiglitazone: another perspective

  2008cites this paper
• Drug Class Review: Thiazolidinediones: Final Report Update 1

  2008cites this paper
• Thiazolidinediones: Antidiabetic Drugs with Cardiovascular Effects

  2008cites this paper
• Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus.

  2007cites this paper
• Pharmacotherapy of Diabetes

  2007cites this paper
• The Glitazones, Lessons so Far

  2007cites this paper
• Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus

  2007cites this paper
• Traitement médicamenteux du diabète de type 2 (deuxième partie)

  2007cites this paper
• Thiazolidinediones and Heart Failure

  2007cites this paper
• PPARγ agonists: safety issues in heart failure

  2007cites this paper
• [Drug treatment of type 2 diabetes].

  2007cites this paper
• Chapter 24 – Insulin-Sensitizing and Insulin-Sparing Drugs: Thiazolidinediones and Metformin

  2006cites this paper
• Kidney‐specific gene targeting: Insight into thiazolidinedione‐induced fluid retention (Review Article)

  2006cites this paper
• Do thiazolidinediones cause heart failure? A critical review.

  2006cites this paper
• Thiazolidinediones: antidiabetic drugs with cardiovascular effects.

  2006cites this paper
• Consensus Statement From the American Heart Association and American Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A

  2006cites this paper
• Heart failure, diabetes and the thiazolidinediones: an unfolding story

  2005cites this paper
• Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone.

  2005cites this paper
• Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome

  2005cites this paper
• Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.

  2005cites this paper
• Nuclear Peroxisome Proliferator-Activated Receptors and Thiazolidinediones

  2005cites this paper
• Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?

  2005cites this paper
• Risk of Hospitalization for Heart Failure Associated with Thiazolidinedione Therapy: A Medicaid Claims–Based Case‐Control Study

  2005cites this paper
• CHARACTERIZATION OF CYTOCHROME P450 2C8 ACTIVITY IN VIVO: PHARMACOGENETIC AND PHARMACOKINETIC STUDIES OF ROSIGLITAZONE METABOLISM

  2005cites this paper
• Impaired Glucose Metabolism in Patients with Heart Failure

  2004cites this paper
• Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

  2004influential citation
• Rosiglitazone and Heart Failure: Long-Term Vigilance

  2004cites this paper
• Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.

  2004cites this paper
• Insulin resistance and cardiovascular disease: the role of PPARγ activators beyond their anti-diabetic action

  2004cites this paper
• Thiazolidinediones and congestive heart failure—exacerbation or new onset of left ventricular dysfunction?

  2004cites this paper
• Thiazolidinediones as PPAR Agonists

  2004cites this paper
• Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms.

  2004cites this paper
• Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.

  2004cites this paper
• Thiazolidinedione-Induced Congestive Heart Failure

  2004cites this paper
• Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.

  2004cites this paper
• Letters to the EditorThiazolidinedione-Associated Congestive Heart Failure and Pulmonary Edema: In Response

  2004cites this paper
• Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione.

  2004cites this paper
• First reports of adverse drug reactions (ADRs) in recent weeks

  2004cites this paper
• Combined Thiazolidinedione-Insulin Therapy

  2004cites this paper
• Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring?

  2004cites this paper
• The "glitazones": rosiglitazone and pioglitazone.

  2003cites this paper
• Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

  2003cites this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cites this paper
• Considerations for management of fluid dynamic issues associated with thiazolidinediones.

  2003cites this paper
• Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability

  2003cites this paper
• Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.

  2003cites this paper
• Glitazones and heart failure: critical appraisal for the clinician.

  2003cites this paper
• Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure.

  2003cites this paper
• Insulin, glucagon, and hypoglycemic drugs

  2003cites this paper
• Possible Heart Failure Exacerbation Associated with Rosiglitazone: Case Report and Literature Review

  2003influential citation
• Glitazones and heart failure: critical appraisal for the clinician.

  2003cites this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cites this paper
• Thiazolidinedione-associated congestive heart failure and pulmonary edema.

  2003cites this paper
• Do thiazolidinediones cause congestive heart failure?

  2003cites this paper
• Thiazolidinedione‐Induced Edema

  2002cites this paper
• Management of Rosiglitazone-Induced Edema: Two Case Reports and a Review of the Literature

  2002cites this paper
• Peripheral edema.

  2002cites this paper
• Clinical inquiries. How beneficial are thiazolidinediones for diabetes mellitus?

  2002cites this paper
• Cardiomyopathy and heart failure in diabetes.

  2001cites this paper
• A Review of Rosiglitazone in Type 2 Diabetes Mellitus

  2001cites this paper
• Nateglinid und Pioglitazon

  2001cites this paper